[{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"6aea670a-703a-4441-a9ff-cf2cf5b73ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479267","created_at":"2021-01-18T21:30:41.002Z","updated_at":"2024-07-02T16:35:13.759Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","source_id_and_acronym":"NCT04479267","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-03-20"},{"id":"642bd716-2adc-4e1e-9e83-d1fcc5dbe602","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417285","created_at":"2021-03-25T18:07:07.062Z","updated_at":"2024-07-02T16:35:32.080Z","phase":"Phase 1b","brief_title":"A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.","source_id_and_acronym":"NCT02417285","lead_sponsor":"Celgene","biomarkers":" MYC • BCL2 • CD20","pipe":" | ","alterations":" CD20 positive • MYC overexpression • MYC rearrangement","tags":["MYC • BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC overexpression • MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • avadomide (CC-122)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 05/22/2015","start_date":" 05/22/2015","primary_txt":" Primary completion: 05/27/2019","primary_completion_date":" 05/27/2019","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2023-10-23"},{"id":"1ba19375-a278-4a1e-94fc-7fcdc21b85ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100251","created_at":"2021-10-29T13:53:09.517Z","updated_at":"2024-07-02T16:35:57.046Z","phase":"Phase 1","brief_title":"Clinical Trial of WB100 on Advanced Solid Tumor","source_id_and_acronym":"NCT05100251","lead_sponsor":"Zhejiang University","biomarkers":" MYC • CA 19-9","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC positive","tags":["MYC • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WB100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 10/25/2023","study_completion_date":" 10/25/2023","last_update_posted":"2023-01-26"},{"id":"a4ec1eb0-717c-4885-999a-6e9126e9bc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498636","created_at":"2022-08-19T18:11:07.980Z","updated_at":"2024-07-02T16:36:05.112Z","phase":"Phase 1/2","brief_title":"SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression","source_id_and_acronym":"NCT05498636","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • etoposide IV • Xpovio (selinexor) • prednisone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-08-19"},{"id":"2cd939b3-0ad5-4da7-9783-177794412b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01943851","created_at":"2021-01-18T08:48:17.616Z","updated_at":"2024-07-02T16:36:30.033Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies","source_id_and_acronym":"NCT01943851","lead_sponsor":"GlaxoSmithKline","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • CD20 expression","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2020","study_completion_date":" 04/30/2020","last_update_posted":"2021-05-19"},{"id":"3e8d61ce-5436-4030-a690-3833bf9a750d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742988","created_at":"2021-01-18T07:38:21.868Z","updated_at":"2024-07-02T16:36:30.660Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","source_id_and_acronym":"NCT01742988","lead_sponsor":"Curis, Inc.","biomarkers":" MYC • BCL2 • BCL6 • CREBBP","pipe":" | ","alterations":" MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6 • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 10/09/2020","study_completion_date":" 10/09/2020","last_update_posted":"2021-05-06"},{"id":"6f2063a2-1cbe-4a9b-8746-58a9eb5e7adb","acronym":"TAILOR","url":"https://clinicaltrials.gov/study/NCT04555473","created_at":"2021-01-18T21:46:38.032Z","updated_at":"2024-07-02T16:36:40.894Z","phase":"","brief_title":"Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids","source_id_and_acronym":"NCT04555473 - TAILOR","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRCA1 • MYC","pipe":" | ","alterations":" MYC overexpression • MYC expression","tags":["BRCA1 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/12/2020","start_date":" 05/12/2020","primary_txt":" Primary completion: 11/04/2021","primary_completion_date":" 11/04/2021","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2020-09-18"},{"id":"efb6b8cf-538e-4440-8fcd-91d55e221959","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776891","created_at":"2021-01-18T13:37:01.006Z","updated_at":"2024-07-02T16:36:54.684Z","phase":"Phase 2","brief_title":"A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT02776891","lead_sponsor":"University of California, San Francisco","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC overexpression • MYC translocation","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC translocation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/13/2016","start_date":" 06/13/2016","primary_txt":" Primary completion: 04/09/2018","primary_completion_date":" 04/09/2018","study_txt":" Completion: 04/09/2018","study_completion_date":" 04/09/2018","last_update_posted":"2019-10-10"}]